GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scholar Rock Holding Corp (NAS:SRRK) » Definitions » EPS without NRI

Scholar Rock Holding (Scholar Rock Holding) EPS without NRI : $-2.09 (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scholar Rock Holding EPS without NRI?

Scholar Rock Holding's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.59. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.09.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 10.90% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 4.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Scholar Rock Holding's EPS without NRI or its related term are showing as below:

SRRK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.9   Med: -6.9   Max: 10.9
Current: 10.9

During the past 8 years, Scholar Rock Holding's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 10.90% per year. The lowest was -26.90% per year. And the median was -6.90% per year.

SRRK's 3-Year EPS without NRI Growth Rate is ranked better than
56.75% of 1304 companies
in the Biotechnology industry
Industry Median: 5.45 vs SRRK: 10.90

Scholar Rock Holding's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.59. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.09.

Scholar Rock Holding's EPS (Basic) for the three months ended in Mar. 2024 was $-0.59. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.09.


Scholar Rock Holding EPS without NRI Historical Data

The historical data trend for Scholar Rock Holding's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scholar Rock Holding EPS without NRI Chart

Scholar Rock Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -1.85 -2.81 -3.59 -2.26 -1.99

Scholar Rock Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 -0.47 -0.53 -0.50 -0.59

Competitive Comparison of Scholar Rock Holding's EPS without NRI

For the Biotechnology subindustry, Scholar Rock Holding's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scholar Rock Holding's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Scholar Rock Holding's PE Ratio without NRI falls into.



Scholar Rock Holding EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scholar Rock Holding  (NAS:SRRK) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Scholar Rock Holding EPS without NRI Related Terms

Thank you for viewing the detailed overview of Scholar Rock Holding's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Scholar Rock Holding (Scholar Rock Holding) Business Description

Traded in Other Exchanges
Address
301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is Apitegroma which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Executives
Mo Qatanani officer: SVP and Head of Research 301 BINNEY STREET, 3RD FLOOR, C/O SCHOLAR ROCK HOLDING CORP, CAMBRIDGE MA 02142
Caryn Parlavecchio officer: CHRO SCHOLAR ROCK HOLDING CORPORATION, 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Junlin Ho officer: General Counsel 301 BINNEY STREET, CAMBRIDGE MA 02142
Edward H Myles director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Samsara Biocapital Gp, Llc 10 percent owner 251 CHURCHILL AVENUE, PALO ALTO CA 94301
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Tracey Sacco officer: Chief Commercial Officer 301 BINNEY STREET, 3RD FLOOR, C/O SCHOLAR ROCK HOLDING CORP, CAMBRIDGE MA 02142
Richard Brudnick director BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Jing L. Marantz officer: Chief Medical Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jay T. Backstrom officer: CEO-Elect SCHOLAR ROCK HOLDING CORPORATION, 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Amir Nashat director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Samsara Biocapital, L.p. 10 percent owner 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661